Treating organoids with SFAs and observing the activation of NF-κB and subsequent changes in cell behavior (such as proliferation, apoptosis, and differentiation) can help understand the impact of SFAs on the tumor microenvironment and the progression of prostate cancer. This evidence concerns the gene NFKB1 and Familial prostate cancer.